Blueprint Medicines Corp [BPMC] stock is trading at $79.22, down -1.22%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BPMC shares have lost -7.82% over the last week, with a monthly amount drifted -8.62%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On March 17, 2025, Jefferies initiated with a Buy rating and assigned a price target of $135 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $150 on March 07, 2025. JP Morgan initiated its recommendation with a Overweight and recommended $126 as its price target on November 14, 2024. UBS started tracking with a Neutral rating for this stock on October 24, 2024, and assigned it a price target of $88. In a note dated May 14, 2024, Stephens initiated an Overweight rating and provided a target price of $140 on this stock.
Blueprint Medicines Corp [BPMC] stock has fluctuated between $76.50 and $121.90 over the past year. Currently, Wall Street analysts expect the stock to reach $124.33 within the next 12 months. Blueprint Medicines Corp [NASDAQ: BPMC] shares were valued at $79.22 at the most recent close of the market. An investor can expect a potential return of 56.94% based on the average BPMC price forecast.
Analyzing the BPMC fundamentals
Blueprint Medicines Corp [NASDAQ:BPMC] reported sales of 508.82M for the trailing twelve months, which represents a growth of 103.41%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.34%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -0.22 and Total Capital is -0.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 76.17 points at the first support level, and at 73.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 83.47, and for the 2nd resistance point, it is at 87.71.
Ratios To Look Out For
For context, Blueprint Medicines Corp’s Current Ratio is 2.85. Further, the Quick Ratio stands at 2.80, while the Cash Ratio is 0.39. Considering the valuation of this stock, the price to sales ratio is 9.95, the price to book ratio is 16.90.
Transactions by insiders
Recent insider trading involved Haviland Kate, CHIEF EXECUTIVE OFFICER, that happened on Apr 01 ’25 when 2498.0 shares were sold. Officer, KATHRYN D HAVILAND completed a deal on Apr 01 ’25 to buy 2498.0 shares. Meanwhile, CHIEF OPERATING OFFICER Rossi Christina sold 2274.0 shares on Mar 24 ’25.
